CEAPRO INC - CRPOF STOCK NEWS

Ceapro Inc. reported its Q1 2024 financial results, showing a decrease in sales to $2.8 million from $3.5 million in Q1 2023. The company highlighted significant progress in R&D, particularly in its Phase 1 clinical study for avenanthramides and the scale-up of PGX technology. The company announced a merger with Aeterna Zentaris, expected to finalize in Q2 2024. The company's gross margin dropped to 44% from 46%, and net loss widened to $1.9 million from $385,000 year-over-year, due to lower sales and increased R&D and G&A expenses. Ceapro maintains a positive working capital of $10.2 million as of March 31, 2024.

Looking ahead, Ceapro aims to complete key projects using its cash reserves and capitalize on the merger benefits.

Ceapro Inc. reported its 2023 financial results and operational highlights, showcasing achievements in R&D, clinical studies, and new product development. The company's sales decreased by 49%, largely due to reorganization with a major customer. Ceapro announced a merger with Aeterna Zentaris to enhance its biopharmaceutical portfolio. Financially, there was a net loss in 2023, impacted by operational changes and lower sales.

Aeterna Zentaris Inc. and Ceapro Inc. announce final court approval for their all-stock merger of equals transaction. The Transaction is expected to be completed in the second quarter of 2024, pending necessary approvals and conditions.

Aeterna Zentaris Inc. and Ceapro Inc. announce the approval of an all-stock merger of equals transaction by their securityholders. The voting results indicate strong support for the merger, with specific resolutions passing with high percentages. The Transaction is expected to close in the second quarter of 2024, pending necessary approvals, leading to the formation of a new entity listed on the Nasdaq and the TSX.

Ceapro Inc. provided an update on its progress, announcing a merger with Aeterna Zentaris Inc. in an all-stock transaction. Ceapro continues to focus on pipeline development, new product development, and technology advancements. The company's clinical trials, product formulations, and commercial launches show promising results. Additionally, Ceapro's PGX Technology for whey proteins presents a cost-effective alternative. Despite challenges in 2023, Ceapro's business outlook appears positive with key developments in various sectors.

Ceapro Inc. announces a special meeting for Securityholders to vote on an all-stock merger of equals with Aeterna Zentaris Inc., creating a combined company listed on Nasdaq and TSX. The merger aims to enhance financial position, revenue streams, product pipeline, and market exposure.

Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) announced the commencement of patient dosing in its Phase 1-2a study for its flagship product, avenanthramides, with no adverse reactions observed. The study is led by Dr. Jean-Claude Tardif at the Montreal Heart Institute and aims to manage conditions related to inflammation. The Phase 1-2a trial will enroll 72 healthy subjects in the Phase 1 portion and 24 patients in the Phase 2a portion to evaluate safety and potential efficacy of avenanthramides.

Ceapro Inc. (CZO) Announces Q3 2023 Sales of $2,619,000, a 32% Decline from Q3 2022, and YTD Sales of $7,983,000, a 48% Decline from 2022

Ceapro Inc. (CZO) announces the initiation of Phase 1-2a study for avenanthramides, a di-phenolic compound found in oats, to evaluate its potential applications in managing conditions related to inflammation. The study, led by Dr. Jean-Claude Tardif at the Montreal Heart Institute, will focus on assessing safety, tolerability, and pharmacokinetics of avenanthramides in healthy subjects, with a potential Phase 2a portion for patients with mild to moderate inflammation. The study aims to provide valuable insights into the potential therapeutic benefits of avenanthramides in cardiovascular disease, with significant market potential and patient benefit, positioning it as a key product for Ceapro.